Avantor Inc. experienced a price increase of 3.74%, reaching a 20-day high, amid positive market conditions with the Nasdaq-100 up 0.33% and the S&P 500 up 0.17%.
This rise is attributed to the upcoming presentation by Avantor's CEO Emmanuel Ligner at the J.P. Morgan Healthcare Conference on January 14, 2026, which is expected to enhance investor engagement and showcase the company's leadership in the life sciences sector. The live-streamed event will provide global investors with insights into Avantor's latest developments, potentially attracting more interest in the company's future growth prospects.
The implications of this presentation are significant, as it not only highlights Avantor's role in the industry but also serves as an opportunity for the company to strengthen its investor relations and transparency, which could lead to increased confidence among stakeholders.
Wall Street analysts forecast AVTR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVTR is 12.30 USD with a low forecast of 8.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
Wall Street analysts forecast AVTR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVTR is 12.30 USD with a low forecast of 8.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
9 Hold
2 Sell
Hold
Current: 11.650
Low
8.00
Averages
12.30
High
17.00
Current: 11.650
Low
8.00
Averages
12.30
High
17.00
TD Cowen
Hold
downgrade
$14 -> $12
2026-01-07
Reason
TD Cowen
Price Target
$14 -> $12
AI Analysis
2026-01-07
downgrade
Hold
Reason
TD Cowen lowered the firm's price target on Avantor to $12 from $14 and keeps a Hold rating on the shares. The firm adjusted targets in the life science tools space as part of a Q4 outlook. While the bar is higher for the Q4 results following the recent share rallies, many companies "already soft guided" 2026, the analyst tells investors in a research note. TD believes this sets room for upside in 2026.
Evercore ISI
Outperform -> In Line
downgrade
$14 -> $12
2026-01-05
Reason
Evercore ISI
Price Target
$14 -> $12
2026-01-05
downgrade
Outperform -> In Line
Reason
Evercore ISI downgraded Avantor to In Line from Outperform with a price target of $12, down from $14.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for AVTR
Unlock Now
Jefferies
Hold
to
Underperform
downgrade
$12 -> $9
2025-12-17
Reason
Jefferies
Price Target
$12 -> $9
2025-12-17
downgrade
Hold
to
Underperform
Reason
Jefferies downgraded Avantor to Underperform from Hold with a price target of $9, down from $12. The firm sees "no quick fix" to the company's market share losses and margin headwinds. Avantor's valuation alone is unlikely to be a catalyst to move the shares higher, the analyst tells investors in a research note.
BofA
Buy -> Neutral
downgrade
$14 -> $13
2025-12-15
Reason
BofA
Price Target
$14 -> $13
2025-12-15
downgrade
Buy -> Neutral
Reason
BofA downgraded Avantor to Neutral from Buy with a price target of $13, down from $14.
About AVTR
Avantor, Inc. is a life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. The Company’s segments include Laboratory Solutions and Bioscience Production. Within its segments, it sells materials and consumables, equipment and instrumentation and services and specialty procurement to customers in the biopharma and healthcare, education and government and advanced technologies and applied materials industries. Materials and consumables include ultra-high purity chemicals and reagents, lab products and supplies, highly specialized formulated silicone materials, customized excipients, and others. Equipment and instrumentation include filtration systems, virus inactivation systems, incubators, analytical instruments, and others. Services and specialty procurement include onsite lab and production, equipment, procurement and sourcing and biopharmaceutical material scale-up and development services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
